Conference Coverage

Rituximab for RA: Think like a European

Publish date: February 24, 2015

 

EXPERT ANALYSIS FROM THE WINTER RHEUMATOLOGY SYMPOSIUM

References

Dr. Weinblatt reported receiving consulting fees or other remuneration from more than two dozen pharmaceutical companies, including Genentech, which markets rituximab.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Smoking impairs biologic response in axial spondyloarthritis
MDedge Internal Medicine
IOM report calls for new criteria, new name for chronic fatigue syndrome
MDedge Internal Medicine
New concerns rise over iatrogenic hydroxychloroquine retinopathy
MDedge Internal Medicine
ACL repair: ‘We have to do better’
MDedge Internal Medicine
VIDEO: As biosimilars arrive in U.S., treatment questions arise
MDedge Internal Medicine
An expert on primary Raynaud’s phenomenon describes treatment approach
MDedge Internal Medicine
How to halt ‘a heart attack of the finger’
MDedge Internal Medicine
Differentiating between primary and secondary Raynaud’s
MDedge Internal Medicine
VIDEO: Ask patients about metal-on-metal hip implants
MDedge Internal Medicine
VIDEO: Homeopathic injectables topped placebo for knee osteoarthritis
MDedge Internal Medicine